Viracta Therapeutics (VIRX) PT Lowered to $4 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Viracta Therapeutics, Inc. (VIRX) Tops Q2 EPS by 12c
August 14, 2024 8:04 AM EDTViracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.
... MoreViracta Therapeutics (VIRX) Reports Positive Data from the Phase 2 NAVAL-1 Trial
August 14, 2024 7:00 AM EDTViracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported positive Phase 2 NAVAL-1 trial results from Stages 1 and 2 of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort. Additionally, the Company received productive feedback from its meeting with the U.S. Food and Drug Administration (FDA), providing clarity on the potential regulatory path to initial registration of Nana-val in patients with R/R EBV+ PTCL. Based on FDAs feedback, Viracta plans to begin... More
